NJ Bio
Address: 675 US Highway 1,, Suite B129, North Brunswick,, NJ. 08902About Us
NJ Bio is a quality CRO that provides integrated chemistry and biology services to clients from the biotech and pharma sectors. Main service areas include multistep organic synthesis, medicinal chemistry, bioconjugation, antibody-drug conjugates, and flow chemistry. The company is headquartered in the New Jersey Bioscience Center in North Brunswick, NJ, with an additional chemistry facility in Bristol, PA. NJ Bio provides flow chemistry services as well as chemical process R&D in collaboration with its affiliate Amar Chemistry Pvt. Ltd. in Mumbai, India.
Sectors
- Contract Research & Development
- Contract Manufacturing
Categories
- Biologics
- Biotechnology
- Chemistry Services
- Medicinal Chemistry
- Chemical Intermediates
- Fine Chemicals
- Process Development
- Proteins
- Antibodies-monoclonals
- Oligonucleotides
- Nucleic Acids
- Antibody Drug Conjugates
- Drug Conjugates & Linkers
- Bioconjugation
- Messenger RNA
- Bioanalysis
- Chemical Synthesis-cGMP
- Small Molecule Synthesis
- Analytical Method Development & Validation
- Small Scale Synthesis
News
NJ Bio, Inc. and Ajinomoto Bio-Pharma Services Partner to Advance ADC and AOC Development
NJ Bio, Inc. and Ajinomoto Bio-Pharma Services have announced a collaboration aimed at expanding access to advanced antibody-drug conjugate (ADC) technologies for biopharma innovators. Under the agreement, NJ Bio will integrate Ajinomoto’s proprietary AJICAP™ site-specific conjugation platform into its discovery and early development workflows. The partnership is expected to enhance NJ Bio’s capabilities in antibody conjugation and linker technologies, enabling more precise and reproducible development of targeted therapeutics.
NJ Bio believes this technology could address a critical gap in novel site-specific conjugation, spanning ADCs, AOCs and other complex bioconjugates. It offers a scalable conjugation approach without relying on expensive microbial enzymes or column chromatography. AJICAP™ allows for site-specific modification of antibodies without requiring engineering, helping preserve structural integrity while improving pharmacokinetics and therapeutic performance. By incorporating this platform, NJ Bio aims to offer clients a more efficient path from early drug discovery through preclinical development.
NJ Bio Moves Headquarters to Princeton, New Jersey
PRINCETON, N.J.--(BUSINESS WIRE)--NJ Biopharmaceuticals LLC (d/b/a NJ Bio), an expert provider of chemistry and biopharmaceutical services specializing in bioconjugation, custom synthesis, flow chemistry, and process development, announced the move of its headquarters from North Brunswick to Princeton, New Jersey.
The 35,000-square-foot, state-of-the-art laboratory space will be located at 350 Carter Road, at a site formerly occupied by Bristol Myers Squibb. Over time, the company plans to expand further within the same location. Current staff will move from North Brunswick to Princeton, and the facility will be fully operational by July 1, 2021. NJ Bio will continue to operate its facility in Bristol, PA, with plans for future growth at that site, including GMP manufacturing capabilities for small molecules as well as bioconjugation.
Source: The Partnership Tree | https://www.pharmaservicesdirectory.com